13-Nov-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain
10-Nov-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and p
5-Nov-2025 7:30 AM CST - Business Wire Vistagen to Participate in Stifel Healthcare Conference 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. Eastern Time. The Company w
9-Sep-2025 7:30 AM CST - Business Wire Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. The Company will also host one-on-one meetings
7-Aug-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update. We had another productive quarter, advancing key programs across our pipeline, said Shawn Singh, Presid
31-Jul-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a
17-Jun-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fa
12-Jun-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate updat
4-Mar-2025 7:30 AM CST - Business Wire Vistagen to Participate in Stifel 2025 Virtual CNS Forum Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifels 2025 Virtual CNS Forum. Vistagens President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m.
13-Nov-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 second quarter ended September 30, 2025, and provided a corporate update. As we conclude the second quarter of our fiscal year, we are encouraged by our progress and remain
10-Nov-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, November 13, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 second quarter ended September 30, 2025, and p
5-Nov-2025 7:30 AM CST - Business Wire Vistagen to Participate in Stifel Healthcare Conference 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation at the Stifel Healthcare Conference on Wednesday, November 12 from 3:20-3:50 p.m. Eastern Time. The Company w
9-Sep-2025 7:30 AM CST - Business Wire Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry Conference. The Company will also host one-on-one meetings
7-Aug-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update. We had another productive quarter, advancing key programs across our pipeline, said Shawn Singh, Presid
31-Jul-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a
17-Jun-2025 3:30 PM CST - Business Wire Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fa
12-Jun-2025 7:30 AM CST - Business Wire Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025 Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Tuesday, June 17, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 ended March 31, 2025, and provide a corporate updat
4-Mar-2025 7:30 AM CST - Business Wire Vistagen to Participate in Stifel 2025 Virtual CNS Forum Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that management will participate in Stifels 2025 Virtual CNS Forum. Vistagens President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat presentation on Tuesday, March 18, 2025, at 12 p.m.
